|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: KIF13A |
Gene summary for KIF13A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | KIF13A | Gene ID | 63971 |
| Gene name | kinesin family member 13A | |
| Gene Alias | RBKIN | |
| Cytomap | 6p22.3 | |
| Gene Type | protein-coding | GO ID | GO:0000910 | UniProtAcc | Q9H1H9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 63971 | KIF13A | CA_HPV_3 | Human | Cervix | CC | 2.92e-05 | 1.59e-01 | 0.0414 |
| 63971 | KIF13A | CCI_1 | Human | Cervix | CC | 6.31e-18 | 1.50e+00 | 0.528 |
| 63971 | KIF13A | CCI_2 | Human | Cervix | CC | 5.84e-07 | 9.87e-01 | 0.5249 |
| 63971 | KIF13A | CCI_3 | Human | Cervix | CC | 1.06e-08 | 8.33e-01 | 0.516 |
| 63971 | KIF13A | sample3 | Human | Cervix | CC | 9.09e-03 | 1.23e-01 | 0.1387 |
| 63971 | KIF13A | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.33e-08 | -3.20e-01 | 0.0155 |
| 63971 | KIF13A | HTA11_1938_2000001011 | Human | Colorectum | AD | 8.55e-03 | 4.77e-01 | -0.0811 |
| 63971 | KIF13A | HTA11_347_2000001011 | Human | Colorectum | AD | 2.66e-14 | 8.27e-01 | -0.1954 |
| 63971 | KIF13A | HTA11_411_2000001011 | Human | Colorectum | SER | 2.39e-02 | 6.16e-01 | -0.2602 |
| 63971 | KIF13A | HTA11_1391_2000001011 | Human | Colorectum | AD | 3.79e-04 | 6.58e-01 | -0.059 |
| 63971 | KIF13A | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.18e-09 | -4.01e-01 | 0.294 |
| 63971 | KIF13A | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.58e-03 | 4.72e-01 | 0.281 |
| 63971 | KIF13A | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.34e-43 | -7.55e-01 | 0.3005 |
| 63971 | KIF13A | F007 | Human | Colorectum | FAP | 4.02e-03 | -3.47e-01 | 0.1176 |
| 63971 | KIF13A | A002-C-010 | Human | Colorectum | FAP | 3.07e-05 | 1.43e-01 | 0.242 |
| 63971 | KIF13A | A015-C-203 | Human | Colorectum | FAP | 4.99e-40 | -6.55e-01 | -0.1294 |
| 63971 | KIF13A | A015-C-204 | Human | Colorectum | FAP | 5.49e-05 | -4.33e-01 | -0.0228 |
| 63971 | KIF13A | A014-C-040 | Human | Colorectum | FAP | 2.65e-02 | -2.40e-01 | -0.1184 |
| 63971 | KIF13A | A002-C-201 | Human | Colorectum | FAP | 1.15e-08 | -3.39e-01 | 0.0324 |
| 63971 | KIF13A | A001-C-119 | Human | Colorectum | FAP | 2.91e-06 | -4.48e-01 | -0.1557 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:007238431 | Oral cavity | NEOLP | organelle transport along microtubule | 18/2005 | 85/18723 | 3.45e-03 | 2.05e-02 | 18 |
| GO:000704131 | Oral cavity | NEOLP | lysosomal transport | 22/2005 | 114/18723 | 4.42e-03 | 2.49e-02 | 22 |
| GO:009951821 | Oral cavity | NEOLP | vesicle cytoskeletal trafficking | 15/2005 | 73/18723 | 9.60e-03 | 4.53e-02 | 15 |
| GO:004819310 | Prostate | BPH | Golgi vesicle transport | 102/3107 | 296/18723 | 3.90e-14 | 4.56e-12 | 102 |
| GO:00307059 | Prostate | BPH | cytoskeleton-dependent intracellular transport | 68/3107 | 195/18723 | 3.78e-10 | 1.98e-08 | 68 |
| GO:007265916 | Prostate | BPH | protein localization to plasma membrane | 89/3107 | 284/18723 | 5.00e-10 | 2.56e-08 | 89 |
| GO:199077810 | Prostate | BPH | protein localization to cell periphery | 95/3107 | 333/18723 | 2.78e-08 | 8.13e-07 | 95 |
| GO:00516569 | Prostate | BPH | establishment of organelle localization | 107/3107 | 390/18723 | 3.67e-08 | 1.03e-06 | 107 |
| GO:009015016 | Prostate | BPH | establishment of protein localization to membrane | 77/3107 | 260/18723 | 1.06e-07 | 2.56e-06 | 77 |
| GO:00009109 | Prostate | BPH | cytokinesis | 55/3107 | 173/18723 | 5.81e-07 | 1.15e-05 | 55 |
| GO:00160507 | Prostate | BPH | vesicle organization | 82/3107 | 300/18723 | 1.64e-06 | 2.78e-05 | 82 |
| GO:00516508 | Prostate | BPH | establishment of vesicle localization | 49/3107 | 161/18723 | 9.12e-06 | 1.28e-04 | 49 |
| GO:00988768 | Prostate | BPH | vesicle-mediated transport to the plasma membrane | 43/3107 | 136/18723 | 1.11e-05 | 1.51e-04 | 43 |
| GO:00109705 | Prostate | BPH | transport along microtubule | 47/3107 | 155/18723 | 1.53e-05 | 1.95e-04 | 47 |
| GO:00516488 | Prostate | BPH | vesicle localization | 51/3107 | 177/18723 | 3.20e-05 | 3.61e-04 | 51 |
| GO:00068928 | Prostate | BPH | post-Golgi vesicle-mediated transport | 34/3107 | 104/18723 | 4.14e-05 | 4.43e-04 | 34 |
| GO:00070349 | Prostate | BPH | vacuolar transport | 46/3107 | 157/18723 | 4.86e-05 | 5.07e-04 | 46 |
| GO:00991112 | Prostate | BPH | microtubule-based transport | 49/3107 | 190/18723 | 8.05e-04 | 5.27e-03 | 49 |
| GO:00723844 | Prostate | BPH | organelle transport along microtubule | 26/3107 | 85/18723 | 9.92e-04 | 6.24e-03 | 26 |
| GO:00995183 | Prostate | BPH | vesicle cytoskeletal trafficking | 23/3107 | 73/18723 | 1.22e-03 | 7.41e-03 | 23 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04814 | Lung | MIAC | Motor proteins | 21/507 | 193/8465 | 5.64e-03 | 3.82e-02 | 2.76e-02 | 21 |
| hsa048141 | Lung | MIAC | Motor proteins | 21/507 | 193/8465 | 5.64e-03 | 3.82e-02 | 2.76e-02 | 21 |
| hsa048145 | Oral cavity | NEOLP | Motor proteins | 37/1112 | 193/8465 | 1.06e-02 | 3.54e-02 | 2.22e-02 | 37 |
| hsa0481412 | Oral cavity | NEOLP | Motor proteins | 37/1112 | 193/8465 | 1.06e-02 | 3.54e-02 | 2.22e-02 | 37 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KIF13A | SNV | Missense_Mutation | novel | c.4210N>C | p.Asp1404His | p.D1404H | Q9H1H9 | protein_coding | tolerated(0.06) | possibly_damaging(0.45) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| KIF13A | SNV | Missense_Mutation | novel | c.2327N>A | p.Arg776Gln | p.R776Q | Q9H1H9 | protein_coding | tolerated(0.06) | benign(0.385) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| KIF13A | SNV | Missense_Mutation | c.1257G>C | p.Glu419Asp | p.E419D | Q9H1H9 | protein_coding | deleterious(0.04) | benign(0.014) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| KIF13A | SNV | Missense_Mutation | rs76740306 | c.653N>C | p.Ser218Thr | p.S218T | Q9H1H9 | protein_coding | deleterious(0.01) | probably_damaging(0.989) | TCGA-A2-A0T2-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | xeloda | PD |
| KIF13A | SNV | Missense_Mutation | c.2915A>G | p.His972Arg | p.H972R | Q9H1H9 | protein_coding | tolerated(0.07) | benign(0) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| KIF13A | SNV | Missense_Mutation | novel | c.4270N>C | p.Asp1424His | p.D1424H | Q9H1H9 | protein_coding | deleterious(0.03) | possibly_damaging(0.593) | TCGA-A7-A4SA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
| KIF13A | SNV | Missense_Mutation | c.1252G>A | p.Glu418Lys | p.E418K | Q9H1H9 | protein_coding | deleterious(0) | possibly_damaging(0.574) | TCGA-A7-A56D-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| KIF13A | SNV | Missense_Mutation | rs76740306 | c.653G>C | p.Ser218Thr | p.S218T | Q9H1H9 | protein_coding | deleterious(0.01) | probably_damaging(0.989) | TCGA-A8-A06R-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| KIF13A | SNV | Missense_Mutation | c.478N>G | p.Leu160Val | p.L160V | Q9H1H9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| KIF13A | SNV | Missense_Mutation | novel | c.4094C>T | p.Ala1365Val | p.A1365V | Q9H1H9 | protein_coding | deleterious(0.02) | possibly_damaging(0.601) | TCGA-B6-A0RM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |